Another feature of PDAC is common genetic modifications driving cancer development and growth, with almost ubiquitous activating mutations of the KRAS oncogene and frequent inactivating mutations of TP53 and CDKN2A tumor suppressor genes. Here, CDKN2A is linked to cancer.